Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | GPR183 | P32249 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090771 | 0.92 | KMT2A (0.40) | KMT2ANPC1MEN1HCRTR2PARP1 | |
| SCHEMBL3543083 | 0.87 | ACHE (0.36) | KMT2ANPC1MEN1ABCB1ROCK2 | |
| SCHEMBL3548729 | 0.84 | ABCB1 (0.36) | PARP1ABCB1 | |
| SCHEMBL3546929 | 0.81 | HCRTR1 (0.40) | KMT2AMEN1HCRTR2HCRTR1ABCB1 | |
| SCHEMBL5094562 | 0.80 | CYP26A1 (0.37) | KMT2ANPC1MEN1HCRTR2HCRTR1 | |
| SCHEMBL3778768 | 0.72 | LDHA (0.35) | KMT2AMEN1 | |
| SCHEMBL2794818 | 0.72 | LDHA (0.35) | KMT2AMEN1 | |
| SCHEMBL2795622 | 0.69 | MTNR1A (0.36) | KMT2A | |
| Oxalic Acid SCHEMBL3548498 | 0.67 | BCHE (0.61) | — | |
| SCHEMBL3807960 | 0.67 | KMT2A (0.41) | KMT2AMEN1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718672-B2 | Substituted tetrahydroisoquinoline compounds, methods of making, and their use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080033007-A1 | Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy | MILLER DUANE D | 2008-02-07 | — | — | US | disclosed |
| US-20070270460-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE | MILLER DUANE D | 2007-11-22 | — | — | US | disclosed |
| US-7241774-B2 | Substituted tetrahydroisoquinoline compounds, methods of making, and their use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1483233-A4 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE | UNIV TENNESSEE RES CORP (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1483233-A2 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE | The University of Tennessee Research Corporation (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040019078-A1 | Substituted tetrahydroisoquinoline compounds, methods of making, and their use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION,THE | 2004-01-29 | — | — | US | disclosed |
| WO-2003077874-A2 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033007-A1 | Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy | BAD, TP53, MCL1 | CFD 4874/4885F11 4782/4885KMT2A 1046/4885 |
| US-20070270460-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE | BAX, CASP3, BAD | CFD 4872/4885F11 4833/4885KMT2A 1317/4885 |
| US-20040019078-A1 | Substituted tetrahydroisoquinoline compounds, methods of making, and their use | BAD, BAX, CASP3 | CFD 4852/4885F11 4819/4885KMT2A 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.